Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15705177 | 1.00 | SIGMAR1 (0.48) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL12050576 | 1.00 | SIGMAR1 (0.48) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL837472 | 1.00 | SIGMAR1 (0.48) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL13140814 | 0.84 | SIGMAR1 (0.38) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL13118761 | 0.84 | SIGMAR1 (0.38) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL14479839 | 0.84 | SIGMAR1 (0.38) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL14390775 | 0.82 | EPHX1 (0.41) | SIGMAR1TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL12327092 | 0.82 | SIGMAR1 (0.37) | SIGMAR1TAAR1SLC18A2 | |
| SCHEMBL6443708 | 0.79 | MOGAT2 (0.38) | SIGMAR1 | |
| SCHEMBL13536230 | 0.79 | CTRB1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | SIGMAR1 4217/4885TAAR1 4780/4885SLC18A2 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.